| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Internal Medicine I, 2 Internal Medicine II, and 3 Immunology, Eberhard Karls University, Tuebingen, Germany
Requests for reprints: Michael Bitzer, Department of Internal Medicine I, Medical University Clinic, Otfried-Mueller-Str. 10, D-72076 Tuebingen, Germany. Phone: 49-7071-298-2712; Fax: 49-7071-295-692; E-mail: michael.bitzer{at}uni-tuebingen.de.
Natural killer (NK) cells as components of the innate immunity substantially contribute to antitumor immune responses. However, the tumor-associated ligands engaging activating NK cell receptors are largely unknown. An exception are the MHC class I chain-related molecules MICA and MICB and the UL16-binding proteins (ULBP) which bind to the activating immunoreceptor NKG2D expressed on cytotoxic lymphocytes. A therapeutic induction of NKG2D ligands that primes cancer cells for NK cell lysis has not yet been achieved. By microarray studies, we found evidence that treatment of human hepatocellular carcinoma cells with the histone deacetylase inhibitor (HDAC-I) sodium valproate (VPA) mediates recognition of cancer cells by cytotoxic lymphocytes via NKG2D. VPA induced transcription of MICA and MICB in hepatocellular carcinoma cells, leading to increased cell surface, soluble and total MIC protein expression. No significant changes in the expression of the NKG2D ligands ULBP1-3 were observed. The induction of MIC molecules increased lysis of hepatocellular carcinoma cells by NK cells which was abolished by addition of a blocking NKG2D antibody. Importantly, in primary human hepatocytes, VPA treatment did not induce MIC protein expression. Taken together, our data show that the HDAC-I VPA mediates specific priming of malignant cells for innate immune effector mechanisms. These results suggest the clinical evaluation of HDAC-I in solid tumors such as hepatocellular carcinoma, especially in combination with immunotherapy approaches employing adoptive NK cell transfer.
This article has been cited by other articles:
|
|
 |
|
  D. D. Vo, R. M. Prins, J. L. Begley, T. R. Donahue, L. F. Morris, K. W. Bruhn, P. de la Rocha, M.-Y. Yang, S. Mok, H. J. Garban, et al. Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824 Cancer Res., November 15, 2009; 69(22): 8693 - 8699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. McGilvray, R. A. Eagle, N. F.S. Watson, A. Al-Attar, G. Ball, I. Jafferji, J. Trowsdale, and L. G. Durrant NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting Clin. Cancer Res., November 15, 2009; 15(22): 6993 - 7002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Andresen, K. A. Hansen, H. Jensen, S. F. Pedersen, P. Stougaard, H. R. Hansen, J. Jurlander, and S. Skov Propionic Acid Secreted from Propionibacteria Induces NKG2D Ligand Expression on Human-Activated T Lymphocytes and Cancer Cells J. Immunol., July 15, 2009; 183(2): 897 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cerwenka New twist on the regulation of NKG2D ligand expression J. Exp. Med., February 16, 2009; 206(2): 265 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Pellicciotta, X. Cortez-Gonzalez, R. Sasik, Y. Reiter, G. Hardiman, P. Langlade-Demoyen, and M. Zanetti Presentation of Telomerase Reverse Transcriptase, a Self-Tumor Antigen, is Down-regulated by Histone Deacetylase Inhibition Cancer Res., October 1, 2008; 68(19): 8085 - 8093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Armeanu, M. Krusch, K. M. Baltz, T. S. Weiss, I. Smirnow, A. Steinle, U. M. Lauer, M. Bitzer, and H. R. Salih Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma Clin. Cancer Res., June 1, 2008; 14(11): 3520 - 3528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vales-Gomez, S. E. Chisholm, R. L. Cassady-Cain, P. Roda-Navarro, and H. T. Reyburn Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors Cancer Res., March 1, 2008; 68(5): 1546 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood, February 1, 2008; 111(3): 1428 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Andresen, H. Jensen, M. T. Pedersen, K. A. Hansen, and S. Skov Molecular Regulation of MHC Class I Chain-Related Protein A Expression after HDAC-Inhibitor Treatment of Jurkat T Cells J. Immunol., December 15, 2007; 179(12): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ostberg, B. E. Dayanc, M. Yuan, E. Oflazoglu, and E. A. Repasky Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells J. Leukoc. Biol., November 1, 2007; 82(5): 1322 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Venkataraman, D. Suciu, V. Groh, J. M. Boss, and T. Spies Promoter Region Architecture and Transcriptional Regulation of the Genes for the MHC Class I-Related Chain A and B Ligands of NKG2D J. Immunol., January 15, 2007; 178(2): 961 - 969. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
